• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lenalidomide and venous thrombosis in multiple myeloma.

作者信息

Rajkumar S Vincent, Blood Emily

出版信息

N Engl J Med. 2006 May 11;354(19):2079-80.

PMID:16696148
Abstract
摘要

相似文献

1
Lenalidomide and venous thrombosis in multiple myeloma.来那度胺与多发性骨髓瘤中的静脉血栓形成
N Engl J Med. 2006 May 11;354(19):2079-80.
2
Lenalidomide and venous thrombosis in multiple myeloma.来那度胺与多发性骨髓瘤中的静脉血栓形成
N Engl J Med. 2006 May 11;354(19):2079-80. doi: 10.1056/NEJMc053530.
3
Lenalidomide: new drug. Myeloma: many questions remain unanswered.来那度胺：新药。骨髓瘤：诸多问题仍未得到解答。
Prescrire Int. 2008 Dec;17(98):230-2.
4
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.来那度胺治疗淀粉样变性和多发性骨髓瘤的皮肤不良反应。
Arch Dermatol. 2006 Oct;142(10):1298-302. doi: 10.1001/archderm.142.10.1298.
5
[Thalidomide treatment in multiple myeloma].[沙利度胺治疗多发性骨髓瘤]
Rinsho Ketsueki. 2003 May;44(5):302-12.
6
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.来那度胺联合地塞米松用于一线治疗后多发性骨髓瘤的治疗。
Oncologist. 2008 Oct;13(10):1120-7. doi: 10.1634/theoncologist.2008-0077. Epub 2008 Oct 15.
7
Lenalidomide and its role in the management of multiple myeloma.来那度胺及其在多发性骨髓瘤治疗中的作用。
Expert Rev Anticancer Ther. 2008 Jun;8(6):865-74. doi: 10.1586/14737140.8.6.865.
8
Thalidomide and dexamethasone: therapy for multiple myeloma.沙利度胺与地塞米松：用于治疗多发性骨髓瘤
Expert Rev Anticancer Ther. 2005 Oct;5(5):759-66. doi: 10.1586/14737140.5.5.759.
9
Anticoagulation regimens for thalidomide and lenalidomide.沙利度胺和来那度胺的抗凝方案。
Clin Adv Hematol Oncol. 2006 Sep;4(9):658-9.
10
Cerebral venous thrombosis in an individual with multiple myeloma treated with lenalidomide.来那度胺治疗的多发性骨髓瘤患者发生脑静脉血栓形成。
J Am Geriatr Soc. 2011 Dec;59(12):2371-2. doi: 10.1111/j.1532-5415.2011.03688.x.

引用本文的文献

1
Possible New Candidates Involved to Thalidomide-Related Limbs and Cardiac Defects: A Systems Biology Approach.与沙利度胺相关的肢体和心脏缺陷可能涉及的新候选因素：一种系统生物学方法
Biochem Genet. 2025 Jun;63(3):2140-2160. doi: 10.1007/s10528-024-10790-w. Epub 2024 Apr 30.
2
Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review.来那度胺、硼替佐米和地塞米松诱导疗法治疗新诊断多发性骨髓瘤：实用综述。
Br J Haematol. 2022 Oct;199(2):190-204. doi: 10.1111/bjh.18295. Epub 2022 Jul 7.
3
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
CD38 和 BCMA 双特异性 CAR-T 在复发或难治性多发性骨髓瘤中的高效和安全性。
J Exp Clin Cancer Res. 2022 Jan 3;41(1):2. doi: 10.1186/s13046-021-02214-z.
4
Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.基于靶向蛋白降解的癌症疗法——来那度胺的经验教训。
Nat Rev Clin Oncol. 2021 Jul;18(7):401-417. doi: 10.1038/s41571-021-00479-z. Epub 2021 Mar 2.
5
Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide.老年多发性骨髓瘤患者管理的最新观点：关注来那度胺。
Clin Interv Aging. 2020 May 4;15:619-633. doi: 10.2147/CIA.S196087. eCollection 2020.
6
Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study.接受化疗的多发性骨髓瘤患者的脑血管疾病谱——一项病例对照研究的结果
PLoS One. 2016 Nov 30;11(11):e0166627. doi: 10.1371/journal.pone.0166627. eCollection 2016.
7
Current treatment landscape for relapsed and/or refractory multiple myeloma.复发和/或难治性多发性骨髓瘤的当前治疗现状。
Nat Rev Clin Oncol. 2015 Jan;12(1):42-54. doi: 10.1038/nrclinonc.2014.200. Epub 2014 Nov 25.
8
From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma.从临床试验到临床实践：单药卡非佐米在复发和/或难治性多发性骨髓瘤患者中的不良事件及其管理
Ther Adv Hematol. 2013 Dec;4(6):354-65. doi: 10.1177/2040620713511176.
9
Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database.沙利度胺与来那度胺严重不良反应比较：法国药物警戒数据库分析。
Med Oncol. 2013 Dec;30(4):733. doi: 10.1007/s12032-013-0733-2. Epub 2013 Sep 28.
10
Lenalidomide in the treatment of young patients with multiple myeloma: from induction to consolidation/maintenance therapy.来那度胺治疗年轻多发性骨髓瘤患者：从诱导治疗到巩固/维持治疗
Adv Hematol. 2012;2012:906247. doi: 10.1155/2012/906247. Epub 2012 Jul 11.